Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TPST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-7.15
vs -15.34
Q2.23
N/A
-7.02
vs -10.27
Q3.23
N/A
-6.24
vs -8.58
Q4.23
N/A
-4.42
vs -8.19
Q1.24
N/A
-4.68
vs -7.15
Q2.24
N/A
-5.46
vs -7.02
Q3.24
N/A
-5.33
vs -6.24
Q4.24
N/A
-4.03
vs -4.42
Q1.25
N/A
-3.54
vs -4.68
Q2.25
N/A
-3.74
vs -5.46
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
486K vs NA
Q1.25
NA
486K vs NA
Q2.25
NA
486K vs NA
Return on Equity
QoQ
Q1.23
-73%
-0.73
vs -0.55
Q2.23
-151%
-1.51
vs -0.73
Q3.23
+570%
5.7
vs -1.51
Q4.23
-28%
-0.28
vs 5.7
Q1.24
-38%
-0.38
vs -0.28
Q2.24
-56%
-0.56
vs -0.38
Q3.24
-92%
-0.92
vs -0.56
Q4.24
-72%
-0.72
vs -0.92
Institutionnal Ownership
QoQ
Q1.23
17
17
vs 13
31%
Q2.23
22
22
vs 17
29%
Q3.23
24
24
vs 22
9%
Q4.23
36
36
vs 24
50%
Q1.24
32
32
vs 36
-11%
Q2.24
25
25
vs 32
-22%
Q3.24
32
32
vs 25
28%
Q4.24
37
37
vs 32
16%
globenewswire.com
8 hours ago
zacks.com
12 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Forecast
-2633%2025-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
TPST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.29 ( -3.60%)
Relative Strenght
99
Volume Buzz
-58%
Earning Acce
Yes
Dist 52w H.
84%